457 related articles for article (PubMed ID: 23414607)
1. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Moran AE; Kovacsovics-Bankowski M; Weinberg AD
Curr Opin Immunol; 2013 Apr; 25(2):230-7. PubMed ID: 23414607
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
3. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
4. Striving for synergy: how to improve cancer immunotherapy through multiple agonist costimulation.
Adler AJ; Vella AT
Immunotherapy; 2013 Dec; 5(12):1271-3. PubMed ID: 24283834
[No Abstract] [Full Text] [Related]
5. Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.
Waight JD; Gombos RB; Wilson NS
Hum Antibodies; 2017; 25(3-4):87-109. PubMed ID: 28085016
[TBL] [Abstract][Full Text] [Related]
6. Signaling through OX40 enhances antitumor immunity.
Jensen SM; Maston LD; Gough MJ; Ruby CE; Redmond WL; Crittenden M; Li Y; Puri S; Poehlein CH; Morris N; Kovacsovics-Bankowski M; Moudgil T; Twitty C; Walker EB; Hu HM; Urba WJ; Weinberg AD; Curti B; Fox BA
Semin Oncol; 2010 Oct; 37(5):524-32. PubMed ID: 21074068
[TBL] [Abstract][Full Text] [Related]
7. Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy.
Li W; Zhang X; Zhang C; Yan J; Hou X; Du S; Zeng C; Zhao W; Deng B; McComb DW; Zhang Y; Kang DD; Li J; Carson WE; Dong Y
Nat Commun; 2021 Dec; 12(1):7264. PubMed ID: 34907171
[TBL] [Abstract][Full Text] [Related]
8. Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity.
Zhang P; Tu GH; Wei J; Santiago P; Larrabee LR; Liao-Chan S; Mistry T; Chu ML; Sai T; Lindquist K; Long H; Chaparro-Riggers J; Salek-Ardakani S; Yeung YA
Cell Rep; 2019 Jun; 27(11):3117-3123.e5. PubMed ID: 31189099
[TBL] [Abstract][Full Text] [Related]
9. CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent.
Lee SJ; Rossi RJ; Lee SK; Croft M; Kwon BS; Mittler RS; Vella AT
J Immunol; 2007 Aug; 179(4):2203-14. PubMed ID: 17675480
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
Chester C; Sanmamed MF; Wang J; Melero I
Blood; 2018 Jan; 131(1):49-57. PubMed ID: 29118009
[TBL] [Abstract][Full Text] [Related]
11. The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells.
Ma BY; Mikolajczak SA; Danesh A; Hosiawa KA; Cameron CM; Takaori-Kondo A; Uchiyama T; Kelvin DJ; Ochi A
Blood; 2005 Sep; 106(6):2002-10. PubMed ID: 15941918
[TBL] [Abstract][Full Text] [Related]
12. The use of immunotherapy in the treatment of melanoma.
Achkar T; Tarhini AA
J Hematol Oncol; 2017 Apr; 10(1):88. PubMed ID: 28434398
[TBL] [Abstract][Full Text] [Related]
13. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Curran MA; Kim M; Montalvo W; Al-Shamkhani A; Allison JP
PLoS One; 2011 Apr; 6(4):e19499. PubMed ID: 21559358
[TBL] [Abstract][Full Text] [Related]
14. 4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function.
Lee SJ; Myers L; Muralimohan G; Dai J; Qiao Y; Li Z; Mittler RS; Vella AT
J Immunol; 2004 Sep; 173(5):3002-12. PubMed ID: 15322159
[TBL] [Abstract][Full Text] [Related]
15. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
16. A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.
Ryan JM; Mittal P; Menoret A; Svedova J; Wasser JS; Adler AJ; Vella AT
Cancer Immunol Immunother; 2018 Apr; 67(4):605-613. PubMed ID: 29327109
[TBL] [Abstract][Full Text] [Related]
17. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
Redmond WL; Triplett T; Floyd K; Weinberg AD
PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
[TBL] [Abstract][Full Text] [Related]
18. OX40 Agonist Tumor Immunotherapy Does Not Impact Regulatory T Cell Suppressive Function.
Polesso F; Sarker M; Weinberg AD; Murray SE; Moran AE
J Immunol; 2019 Oct; 203(7):2011-2019. PubMed ID: 31434709
[TBL] [Abstract][Full Text] [Related]
19. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses.
Smith SE; Hoelzinger DB; Dominguez AL; Van Snick J; Lustgarten J
Cancer Immunol Immunother; 2011 Dec; 60(12):1775-87. PubMed ID: 21789593
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of a novel anti-OX40 antibody for potent immune activation.
Kuang Z; Jing H; Wu Z; Wang J; Li Y; Ni H; Zhang P; Wu W; Wu M; Zhou S; Qiu X; Wu D; Prinz B; Baruah H; Chen B; Yu M; Liu J
Cancer Immunol Immunother; 2020 Jun; 69(6):939-950. PubMed ID: 32078015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
